000842641 001__ 842641
000842641 005__ 20210129232416.0
000842641 0247_ $$2Handle$$a2128/16848
000842641 037__ $$aFZJ-2018-00848
000842641 041__ $$aEnglish
000842641 1001_ $$0P:(DE-Juel1)133346$$aSchmitz, Sabine$$b0$$eCorresponding author$$ufzj
000842641 1112_ $$a14. Jahrestagung der Gesellschaft für biologische Strahlenforschung$$cRheinbach$$d2011-09-13 - 2011-09-16$$gGBS$$wGermany
000842641 245__ $$aChromosomal radiosensitivity of lymphocytes of prostate cancer patients and healthy donors analyzed by FISH
000842641 260__ $$c2011
000842641 3367_ $$033$$2EndNote$$aConference Paper
000842641 3367_ $$2BibTeX$$aINPROCEEDINGS
000842641 3367_ $$2DRIVER$$aconferenceObject
000842641 3367_ $$2ORCID$$aCONFERENCE_POSTER
000842641 3367_ $$2DataCite$$aOutput Types/Conference Poster
000842641 3367_ $$0PUB:(DE-HGF)24$$2PUB:(DE-HGF)$$aPoster$$bposter$$mposter$$s1517207785_23350$$xAfter Call
000842641 520__ $$aAbstract: Background: It is known that about 10 % of cancer patients show severe clinical side effects during and after radiotherapy due to enhanced sensitivity to ionizing radiation. Identification of those radiosensitive individuals by an in vitro assay before onset of treatment would be of great impact for successful radiotherapy.In this study we compared the radiosensitivity of the chromosomes 2, 11 and 17 in prostate cancer patients with and without severe side effects after radiotherapy and in age-matched healthy donors (control cohort). The chromosomal radiosensitivity of peripheral blood lymphocytes (PBL) of radiotherapy patients was used as predictive parameter for clinical side effects.Material und Methods: Each cohort consisted of at least 10 donors. PBL were irradiated ex vivo with 0.5, 1 und 2 Gy (Cs-137 -rays) in the G0-Phase of the cell cycle. We analyzed the radiosensitivity of the chromosomes 2, 11 and 17 by scoring of 100 FISH painted metaphases for each dose point. Statistical analyses were performed by non-parametric Mann-Whitney test, by test of variances (ANOVA) and Chi-square goodness-of-fit test at a significance level of 0.05. Results: Analysis of the overall aberration yield revealed no significant differences between any donor groups. However, variance analyses showed significant differences between the patient’s cohort and healthy donors for chromosomes 11 and 17 for all doses analyzed. In contrast, this was not true for chromosome 2. Furthermore, good correlations between chromosomes sizes (DNA content) and aberration yield were found.Conclusion: The cohort of prostate cancer patients can be distinguished from healthy donors due to variances of the aberration yields of the chromosomes 11 and 17. These chromosomes might be potential cytogenetic biomarkers for prostate cancer patients in clinical studies.Funded by Dr. Erich-Schmitt-Foundation
000842641 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000842641 65027 $$0V:(DE-MLZ)SciArea-160$$2V:(DE-HGF)$$aBiology$$x0
000842641 7001_ $$0P:(DE-HGF)0$$aBrzozowska, Kinga$$b1
000842641 7001_ $$0P:(DE-HGF)0$$aPinkawa, Michael$$b2
000842641 7001_ $$0P:(DE-HGF)0$$aEble, Michael$$b3
000842641 7001_ $$0P:(DE-Juel1)133469$$aKriehuber, Ralf$$b4$$ufzj
000842641 8564_ $$uhttps://juser.fz-juelich.de/record/842641/files/Schmitz%20et%20al%20GBS%202011%20Rheinbach.pdf$$yOpenAccess
000842641 8564_ $$uhttps://juser.fz-juelich.de/record/842641/files/Schmitz%20et%20al%20GBS%202011%20Rheinbach.gif?subformat=icon$$xicon$$yOpenAccess
000842641 8564_ $$uhttps://juser.fz-juelich.de/record/842641/files/Schmitz%20et%20al%20GBS%202011%20Rheinbach.jpg?subformat=icon-1440$$xicon-1440$$yOpenAccess
000842641 8564_ $$uhttps://juser.fz-juelich.de/record/842641/files/Schmitz%20et%20al%20GBS%202011%20Rheinbach.jpg?subformat=icon-180$$xicon-180$$yOpenAccess
000842641 8564_ $$uhttps://juser.fz-juelich.de/record/842641/files/Schmitz%20et%20al%20GBS%202011%20Rheinbach.jpg?subformat=icon-640$$xicon-640$$yOpenAccess
000842641 8564_ $$uhttps://juser.fz-juelich.de/record/842641/files/Schmitz%20et%20al%20GBS%202011%20Rheinbach.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000842641 909CO $$ooai:juser.fz-juelich.de:842641$$pdriver$$pVDB$$popen_access$$popenaire
000842641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133346$$aForschungszentrum Jülich$$b0$$kFZJ
000842641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-HGF)0$$aForschungszentrum Jülich$$b1$$kFZJ
000842641 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a S-US$$b1
000842641 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-HGF)0$$aRWTH Aachen$$b2$$kRWTH
000842641 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universitätsklinik für Strahlentherapie$$b2
000842641 9101_ $$0I:(DE-588b)36225-6$$6P:(DE-HGF)0$$aRWTH Aachen$$b3$$kRWTH
000842641 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Universitätsklinik für Strahlentherapie$$b3
000842641 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133469$$aForschungszentrum Jülich$$b4$$kFZJ
000842641 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000842641 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000842641 920__ $$lyes
000842641 9201_ $$0I:(DE-Juel1)S-US-20090406$$kS-US$$lSicherheit und Strahlenschutz, Umgebungsüberwachung,Strahlenbiologie$$x0
000842641 980__ $$aposter
000842641 980__ $$aVDB
000842641 980__ $$aUNRESTRICTED
000842641 980__ $$aI:(DE-Juel1)S-US-20090406
000842641 9801_ $$aFullTexts